Matinas BioPharma (OTCQB: MTNB) is a development stage biopharmaceutical company, founded in 2011, with a focus on identifying and developing novel pharmaceutical products for the treatment of abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular and metabolic diseases. Matinas is building on the extensive and proprietary research and development capabilities of its founding management team. The Matinas BioPharma team brings a cumulative multi-decade omega-3 pharmaceutical development and commercialization experience to the Company, providing a unique perspective and capability for creating the next generation of omega-3-fatty-acid-based pharmaceutical products. SNNLive spoke with Roelof Rongen, Co-Founder, President and CEO of Matinas BioPharma Holdings, Inc. at The FireRock Conference 2014 in New York City, NY.
"Matinas BioPharma was formed by my former colleagues that launched Lovaza at Reliant Pharmaceuticals. Lovaza became a billion dollar Omega-3 product. We learned a lot about this space, and we think we have understood how to differentiate a new product in this space with very unique Omega-3 fatty acids that we developed with a proprietary technology," Mr. Rongen begins.
Mr. Rongen explains that, “Matinas is focusing on rare omega-3 fatty acids, these are not your typical fish oil fatty acids, these are unique molecules that have their own biological role and what we uncovered, what you can also see in scientific research is that they have very unique biological functionality.”
What Matinas has done is they have, “developed a process to make these rare fatty-acids because you cannot get them out of a natural source - it’s like getting gold out of sea water.” Looking forward to 2015, “I think the unique part about Matinas Biopharma’s development program for MAT9001 is its very short time span, our goal is to go very soon into phase III next year 2015, get the completion and file our NDA in late 2016, early 2017.” For more information, click here: www.MatinasBioPharma.com
© 2017 Stock News Now
Supported by Superior Web Solutions